Patients Meeting Control Targets for Glycosylated Hemoglobin and Cardiovascular Risk Factors
| Control Target* | Frequency | Percent of Total |
|---|---|---|
| HbA1c = glycosylated hemoglobin; ADA = American Diabetes Association; JNC 7 = The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; LDL-C = low-density lipoprotein cholesterol. | ||
| Note: Percentage is based on cases where data were available and provided. Missing data rates are 6.1% for HbA1c, 1.7% for blood pressure, and 18.4% for LDL-C. Data are from visit monitoring forms. | ||
| * Based on American Diabetes Association target for adults with type-2 diabetes.14 | ||
| † Based on the JNC 7 for blood pressure.16 | ||
| HbA1c | ||
| <7.0% | 313 | 40.5 |
| 7.0% to 7.9% | 217 | 28.1 |
| 8.0% to 8.9% | 109 | 14.1 |
| 9.0% to 9.9% | 61 | 7.9 |
| ≥ 10.0% | 72 | 9.3 |
| Blood pressure: ADA target | ||
| Systolic <130 mm Hg and diastolic <85 mm Hg | 285 | 35.3 |
| Blood pressure: JNC 7 categories† | ||
| Normal (systolic <120 mm Hg and diastolic <80 mm Hg) | 146 | 18.1 |
| Prehypertension (systolic 120–139 mm Hg or diastolic 80–90 mm Hg) | 452 | 55.9 |
| Stage 1 hypertension (systolic 140–159 mm Hg or diastolic 90–99 mm Hg) | 176 | 21.8 |
| Stage 2 hypertension (systolic ≥ 160 mm Hg or diastolic ≥ 100 mm Hg) | 34 | 4.2 |
| LDL-C | ||
| <100 mg/dL | 294 | 43.8 |
| 100–129 mg/dL | 198 | 29.5 |
| 130–159 mg/dL | 105 | 15.7 |
| 160–189 mg/dL | 52 | 7.8 |
| ≥ 190 mg/dL | 22 | 3.3 |
| Combined targets | ||
| HbA1c (<7%) and LDL-C (<100 mg/dL) | 111 | 16.7 |
| HbA1c (<7%) and blood pressure (<130/85 mm Hg) | 104 | 13.7 |
| HbA1c (<7%) and blood pressure (<130/85 mm Hg) and LDL-C (<100 mg/dL) | 45 | 7.0 |